Development of a Selective Peptide Macrocycle Inhibitor of Coagulation Factor XII toward the Generation of a Safe Antithrombotic Therapy.
Data(s) |
2013
|
---|---|
Resumo |
Inhibition of coagulation factor XII (FXII) activity represents an attractive approach for the treatment and prevention of thrombotic diseases. The few existing FXII inhibitors suffer from low selectivity. Using phage display combined to rational design, we developed a potent inhibitor of FXII with more than 100-fold selectivity over related proteases. The highly selective peptide macrocycle is a promising candidate for the control of FXII activity in antithrombotic therapy and a valuable tool in hematology research. |
Identificador |
http://serval.unil.ch/?id=serval:BIB_73BC92D2A3DA isbn:1520-4804 (Electronic) pmid:23586812 doi:10.1021/jm400236j isiid:000318892500028 |
Idioma(s) |
en |
Fonte |
Journal of Medicinal Chemistry, vol. 56, no. 9, pp. 3742-3746 |
Tipo |
info:eu-repo/semantics/article article |